Equites Radar

ZBH · Zimmer Biomet Holdings, Inc.

Medical DevicesUnited StatesAnalyst view: Buy

$91.35

+4.00% last session

End-of-day data · updated 2026-07-28

Mildly bullish3 bullish · 1 bearish technical signals
Consensus: Buy (2.46 from 20 analysts)
To mean target: +7.9%

Market cap

$18B

Enterprise value

$25B

Trailing P/E

23.9

Forward P/E

10.2

Dividend yield

1.0%

Beta

0.46

Avg volume

2M

Employees

17K

2D change

5D change

2.70%

10D change

1.04%

30D change

-1.11%

60D change

12.13%

MTD change

9.39%

YTD change

2.94%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)2.46
Covering analysts20
Mean price target$98.60
Low price target$83.00
Upside to mean target+7.9%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)62.0
50-day MA$87.78
200-day MA$90.71
Price vs 50-day MA+9.1%
Price vs 200-day MA+5.6%
MACD histogram0.21
Volume vs 3-month avg1.3×
52w low $79.3752w high $106.59

Analyst sentiment over time — ZBH

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-09

Latest call per bank · past 12 months

Citigroup

Neutral

$93.00

+1.8% vs price
▼ cut from $95.00Maintains · 2026-05-28

JP Morgan

Neutral

$95.00

+4.0% vs price
▼ cut from $100Maintains · 2026-04-29

Wells Fargo

Equal-Weight

$90.00

-1.5% vs price
▼ cut from $98.00Maintains · 2026-04-29

Barclays

Underweight

$94.00

+2.9% vs price
▼ cut from $100Maintains · 2026-04-29

UBS

Sell

$86.00

-5.9% vs price
▼ cut from $88.00Maintains · 2026-01-28

RBC Capital

Outperform

$101

+10.6% vs price
▼ cut from $111Maintains · 2025-11-06

Recent rating actions

DateFirmActionRatingPrice target
2026-07-09BMO CapitalInitiatesOutperformMarket Perform$0.00 $95.00
2026-07-06Evercore ISI GroupMaintainsOutperform$120 $110
2026-05-28CitigroupMaintainsNeutral$95.00 $93.00
2026-04-29JP MorganMaintainsNeutral$100 $95.00
2026-04-29CitigroupMaintainsNeutral$98.00 $95.00
2026-04-29CitizensMaintainsMarket Outperform$120 $105
2026-04-29Wells FargoMaintainsEqual-Weight$98.00 $90.00
2026-04-29BarclaysMaintainsUnderweight$100 $94.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 62 — neutral momentum, neither overbought nor oversold.
  • Price vs 50-day MA: Trading 9.1% above the 50-day MA ($87.78).
  • Price vs 200-day MA: Trading 5.6% above the 200-day MA ($90.71).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.21) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($79.37) and high ($106.59).

ZBH Price Chart

Loading chart for ZBH

Fundamentals

Revenue (TTM)$8.0B
EBITDA$3.0B
Free cash flow$1.0B
Operating cash flow$2.0B
Book value / share$65.53
Net debt / EBITDA2.8
WACC7.0%
Revenue growth9.00%
Earnings growth34.00%

About Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, healthcare institutions, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. It also offers ROSA Robot, which utilizes robotic technologies to assist a surgeon with implant positioning in total knee arthroplasty or partial knee arthroplasty; and the ZBEdge Platform connects robotic and digital technologies together to collect data before, during and after surgery, that can deliver insights to surgeons to assist in making informed decisions on patient care. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

More in Medical Devices

Screen ZBH against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.